Deep Dive
GLP-1s: The Second-Order Investing Implications
Mar 15, 2026 · 22 min read · Winvestor Analyst Team
The market has fully priced the GLP-1 manufacturers. What it has not priced is the cascade of second-order effects across food, beverage, medical devices, and life insurance. We map the winners and losers.
The base case for utilization
We model 35-45 million U.S. adults on GLP-1 therapy by 2030, up from roughly 12 million today. The constraint is not demand or efficacy — it is manufacturing capacity and payer willingness, both of which are loosening quickly.
Food and beverage
Per-capita caloric intake among GLP-1 users falls 20-30%, with disproportionate cuts to alcohol, snacks, and sugary beverages. Companies with portfolios heavy in those categories face a structural — not cyclical — volume headwind. Several have begun reformulating, but the math on margin pressure is unforgiving.
Restaurants and convenience retail
Casual dining chains and convenience store operators face a smaller but still meaningful headwind. Survey data shows GLP-1 users reduce restaurant visit frequency by 12-18% and average ticket size by 8-12%. The pain is concentrated in operators with heavy alcohol and dessert mix. Operators with strong beverage and healthy-option pivots have outperformed by 600+ bps over the past year — a gap we expect to widen.
Medical devices and procedure volumes
Obesity-linked procedure volumes (bariatric surgery, knee replacements, sleep apnea devices) are inflecting in opposite directions depending on the device. We see clear winners in cardio rhythm and clear losers in bariatric hardware. The dispersion within the sector is the largest in a decade.
Cardiometabolic and pharmacy benefits
Companies in CV outcomes, lipid management, and diabetes care face mixed effects: lower volumes per patient over time but a larger eligible population. Pharmacy benefit managers gain meaningful incremental revenue from GLP-1 dispensing but face margin compression as biosimilar and oral formulations come to market post-2027. Net effect is positive in the near term but more nuanced beyond.
Insurance and longevity
Mortality improvements from sustained weight reduction would meaningfully extend lifespans of insured cohorts. Life insurers benefit; long-duration annuity writers face a slow-moving but material liability extension. Reserving practices have not yet caught up.
Manufacturing capacity and supply chain
The supply chain serving GLP-1 production — auto-injector pen suppliers, specialty contract manufacturers, glass vial producers, cold-chain logistics — has multi-year visibility and pricing power. Many of these names are off the radar of generalist investors yet trade at reasonable multiples relative to their growth profile. We see this as one of the cleaner second-order plays.
Time horizon and position sizing
Second-order effects play out over 3-7 years, not 3-7 quarters. Position sizing should reflect that — large enough to matter if right, small enough to tolerate the noise. We typically size these positions at 1.5-3% each and accept that the path to the thesis playing out will include extended periods of underperformance.